Neurotech company Paradromics has initiated a new programme to drive academia’s access to its brain-computer interface (BCI) to advance innovation in the device space.
Paradromics lead product is Connexus BCI, a technology designed to record and decode brain signals to help implanted patients with speech restoration. In November 2025, the US Food and Drug Administration (FDA) granted Paradromics an investigational device exemption (IDE) to initiate its Connect-One Early Feasibility Study (EFS) – mooted to begin in H1 2026.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Texas-headquartered Paradromics’ Application Expansion (APEX) partnership programme gives academic collaborators access to its Connexus BCI, with a view to driving progress in applications of the technology in areas such as motor and sensory restoration, BCI-based controllers for complex systems, and speech restoration for people who have lost the muscle control needed to talk.
Paradromics chief scientific officer, Vikash Gilja said: “The APEX partnership programme builds a vibrant ecosystem where scientific discovery and medical device development move hand-in-hand.”
Gilja asserted that by aligning academic innovation with Paradromics’ BCI platform, the company and its academic collaborators can “bring life-changing technology to people faster”.
Advancing the BCI space through collaboration
Paradromics APEX programme comes on the heels of a similar initiative recently introduced by Science Corporation to help BCI industry peers advance their developmental work on BCI technologies by enhancing device access. In February 2026, Swiss BCI developer Neurosoft Bioelectronics became the inaugural inductee into Science’s programme.
GlobalData analysis reveals that the global neurology devices market is projected to reach a valuation above $25bn in 2034.
Within this market segment in the healthcare space, BCI technologies are determined to be on a rapid growth course. Morgan Stanley estimates there to be an early total addressable market (TAM) of $80bn across three million US adults for BCI technology, potentially reaching $320bn with further advancements.
Neuralink, the BCI company helmed by serial entrepreneur Elon Musk, has drawn the majority of the sector’s attention for developmental products such as Telepathy, a BCI that gives amputees the ability to control hardware such as computers and robotic limbs using only their thoughts
However, a broad range of companies are involved in the BCI space. These include Synchon, InBrain Neuroelectronics, and Neurosoft, which are developing BCI technology to address conditions such as severe paralysis and Parkinson’s disease.
